FDA Approves Margetuximab for Patients with Metastatic HER2+ Breast Cancer

On December 16, 2020, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Read the FDA announcement.

Read MacroGenics' announcement.

Posted 12/17/2020